✦ LIBER ✦

Favorable early response of secondary chronic myeloid leukemia to imatinib

✍ Scribed by Dalia Waldman; Michael Weintraub; Arnold Freeman; Yoram Neumann; Gideon Rechavi; Amos Toren

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 62 KB
Volume: 75
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.20027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dasatinib early intervention after cytog

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

✍ Alfonso Quintás-Cardama; Jorge E. Cortes; Susan O'Brien; Farhad Ravandi; Gautam 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 2 views

Chronic myeloid leukemia in a patient wi

Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: Rapid response to imatinib mesylate (STI571)

✍ Imashuku, Shinsaku ;Morimoto, Akira ;Kuriyama, Kikuko ;Kano, Gen ;Hibi, Shigeyos 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

XPC genetic polymorphisms correlate with

XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia

✍ Vicent M. Guillem; Francisco Cervantes; Jesús Martínez; Alberto Alvarez-Larrán; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Significance of suboptimal response to i

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

✍ Yesid Alvarado; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Gautam Borthakur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 2 views

## Abstract ## BACKGROUND: The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined. ## METHODS: The significance of having had a suboptimal response during

RAD 001 (everolimus) prevents mTOR and A

RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia

✍ Manuela Mancini; Sara Petta; Giovanni Martinelli; Enza Barbieri; Maria A. Santuc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB

## Abstract The mammalian target of rapamycin (mTOR) is one target of BCR‐ABL fusion gene of chronic myeloid leukemia (CML). Moreover, it drives a compensatory route to Imatinib mesylate (IM) possibly involved in the progression of leukemic progenitors towards a drug‐resistant phenotype. Accordingl

Efficacy and safety of imatinib in patie

Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α

✍ Susan Branford; Timothy Hughes; Alvin Milner; Rachel Koelmeyer; Anthony Schwarer 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 2 views

## Abstract ## BACKGROUND. Interferon‐alpha (IFN‐α) confers a survival advantage for the minority of patients with chronic myeloid leukemia (CML) who achieve a complete cytogenetic response. The question of whether IFN‐α‐responsive patients can experience further improvements with imatinib has not